Author

J. D. Crispino

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Kumar· 1 shared C. Hurtz· 1 shared G. Wertheim· 1 shared H. Geng· 1 shared J. Chukinas· 1 shared J. P. Loftus· 1 shared J. Shi· 1 shared K. M. Bernt· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Kumar

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintOct 2, 2022

Pharmacologic Inhibition of DYRK1A Results in MYC Hyperactivation and ERK Hyperphosphorylation rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

C. Hurtz, V. S. S. A. Ayyadevara, G. Wertheim…·S. K. Tasian

This study shows that inhibiting DYRK1A in KMT2A-R ALL cells leads to MYC upregulation and ERK hyperphosphorylation, making them sensitive to BCL2 inhibition.

DOI 10.1101/2022.10.02.510349

humanproteomics

𝕏 PostBluesky